[Clinical observation on effect of tongnao huoluo acupuncture therapy in treating acute cerebral infarction at ultra-early or acute stage].
OBJECTIVE
To evaluate the efficacy and safety of Tongnao Huoluo acupuncture (TNHLA) therapy in treating acute cerebral infarction at ultra-early stage (within 6 hrs after attack) or acute stage (within 6-48 hrs after attack).


METHODS
The effect of TNHLA in the two stages was observed separately (treated group) and compared with the effect treated with immediate thrombolysis by intravenously given urokinase 12 million units in ultra-early stage or simple body acupuncture in acute stage (control group), and with those treated with intravenous dripping of normal saline (placebo group). In the meantime, all groups treated with low molecular dextran injection for 14 days, cytidine diphosphate choline and entric soluble aspirin for 28 days.


RESULTS
Effect of TNHLA in the treated group was insignificantly different to that after thrombolysis of the control group in the ultra-early stage, but significantly higher than that of body acupuncture in acute stage. The intracranial hemorrhage rates in the treated, control, and placebo group were 3.3%, 4.0%, and 8.0% respectively.


CONCLUSIONS
TNHLA is effective and safe in treating acute cerebral infarction at ultra-early stage or acute stage.
Li
Ji-ying
JY
Center of Cerebro-vascular Diseases, Nanjing Municipal Hospital of TCM, Nanjing 210001. ljydoctor@sina.com
Peng
Yu-zhu
YZ
Yang
Fang
F
D015670:Acupuncture Therapy / Q000379:methods; D000328:Adult; D000368:Aged; D002544:Cerebral Infarction / Q000628:therapy*; D003911:Dextrans / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015912:Thrombolytic Therapy; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D003911:Dextrans; D014568:Urokinase-Type Plasminogen Activator